Literature DB >> 18989350

Privilege revisited: an evaluation of the eye's defence mechanisms.

J V Forrester1.   

Abstract

Immune privilege has been considered for many years to be an interesting phenomenon associated with certain specialised tissues such as the eye and the brain. In recent years however, it has become clear that the active and passive mechanisms which underpin immune privilege are in fact a form of tissue-based immunological tolerance, perhaps of equal importance in providing defence against antigenic attack as the well established mechanisms based on the thymus (central tolerance) and circulating regulatory cells (peripheral tolerance). It would appear that each tissue possesses a degree of intrinsic immunological resistance which varies depending on the tissues and provides some degree of protection. In some tissues, such as the eye, this is protection from 'danger' has been developed to a high level of sophistication, but at a price. The mechanisms involved are presented in his lecture.

Mesh:

Year:  2008        PMID: 18989350     DOI: 10.1038/eye.2008.259

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  11 in total

Review 1.  High-risk corneal allografts: A therapeutic challenge.

Authors:  Tian Yu; Vijayalakshmi Rajendran; May Griffith; John V Forrester; Lucia Kuffová
Journal:  World J Transplant       Date:  2016-03-24

Review 2.  The immune response in glaucoma: a perspective on the roles of oxidative stress.

Authors:  Gülgün Tezel
Journal:  Exp Eye Res       Date:  2010-08-13       Impact factor: 3.467

3.  The living eye "disarms" uncommitted autoreactive T cells by converting them to Foxp3(+) regulatory cells following local antigen recognition.

Authors:  Ru Zhou; Reiko Horai; Phyllis B Silver; Mary J Mattapallil; Carlos R Zárate-Bladés; Wai Po Chong; Jun Chen; Rachael C Rigden; Rafael Villasmil; Rachel R Caspi
Journal:  J Immunol       Date:  2012-01-11       Impact factor: 5.422

4.  Imaging dynamics of CD11c⁺ cells and Foxp3⁺ cells in progressive autoimmune insulitis in the NOD mouse model of type 1 diabetes.

Authors:  Anja Schmidt-Christensen; Lisbeth Hansen; Erwin Ilegems; Nina Fransén-Pettersson; Ulf Dahl; Shashank Gupta; Asa Larefalk; Tine D Hannibal; Alexander Schulz; Per-Olof Berggren; Dan Holmberg
Journal:  Diabetologia       Date:  2013-08-21       Impact factor: 10.122

5.  Ocular Stem Cell Research from Basic Science to Clinical Application: A Report from Zhongshan Ophthalmic Center Ocular Stem Cell Symposium.

Authors:  Hong Ouyang; Jeffrey L Goldberg; Shuyi Chen; Wei Li; Guo-Tong Xu; Wei Li; Kang Zhang; Robert B Nussenblatt; Yizhi Liu; Ting Xie; Chi-Chao Chan; Donald J Zack
Journal:  Int J Mol Sci       Date:  2016-03-22       Impact factor: 5.923

Review 6.  Rebuilding the Missing Part-A Review on Photoreceptor Transplantation.

Authors:  Tiago F Santos-Ferreira; Oliver Borsch; Marius Ader
Journal:  Front Syst Neurosci       Date:  2017-01-05

Review 7.  Cytokine interplay among the diseased retina, inflammatory cells and mesenchymal stem cells - a clue to stem cell-based therapy.

Authors:  Vladimir Holan; Barbora Hermankova; Magdalena Krulova; Alena Zajicova
Journal:  World J Stem Cells       Date:  2019-11-26       Impact factor: 5.326

Review 8.  Plasmacytoid dendritic cells in the eye.

Authors:  Arsia Jamali; Brendan Kenyon; Gustavo Ortiz; Abdo Abou-Slaybi; Victor G Sendra; Deshea L Harris; Pedram Hamrah
Journal:  Prog Retin Eye Res       Date:  2020-07-24       Impact factor: 21.198

9.  Resolvin D1 reduces the immunoinflammatory response of the rat eye following uveitis.

Authors:  Rossi Settimio; Di Filippo Clara; Ferraraccio Franca; Simonelli Francesca; D'Amico Michele
Journal:  Mediators Inflamm       Date:  2012-12-10       Impact factor: 4.711

Review 10.  Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors.

Authors:  Junko Hori; Tomoyuki Kunishige; Yuji Nakano
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.